Rivaroxaban in Rheumatic Heart Disease–Associated Atrial Fibrillation | NEJM


Abstract Background Testing of factor Xa inhibitors for the prevention of cardiovascular events in patients with rheumatic heart disease–associated atrial fibrillation has been limited. Methods We enrolled patients with atrial fibrillation and echocardiographically documented rheumatic heart disease who had any of the following: a CHA2DS2VASc score of at least 2 (on a scale from 0 to 9, with...

Read Complete Article

Post a Comment

Previous Post Next Post